CA2763894A1 - Utilisation de la rifaximine pour maintenir la remission de l'encephalopathie hepatique - Google Patents

Utilisation de la rifaximine pour maintenir la remission de l'encephalopathie hepatique Download PDF

Info

Publication number
CA2763894A1
CA2763894A1 CA2763894A CA2763894A CA2763894A1 CA 2763894 A1 CA2763894 A1 CA 2763894A1 CA 2763894 A CA2763894 A CA 2763894A CA 2763894 A CA2763894 A CA 2763894A CA 2763894 A1 CA2763894 A1 CA 2763894A1
Authority
CA
Canada
Prior art keywords
rifaximin
subject
cff
subjects
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2763894A
Other languages
English (en)
Inventor
William Forbes
Enoch Bortey
Kunal Merchant
Audrey Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Inc
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/572,344 external-priority patent/US20100204173A1/en
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Priority claimed from PCT/US2010/037131 external-priority patent/WO2011005388A1/fr
Publication of CA2763894A1 publication Critical patent/CA2763894A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2763894A 2009-06-02 2010-06-02 Utilisation de la rifaximine pour maintenir la remission de l'encephalopathie hepatique Abandoned CA2763894A1 (fr)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US18351309P 2009-06-02 2009-06-02
US61/183,513 2009-06-02
US12/572,344 US20100204173A1 (en) 2008-10-02 2009-10-02 Methods of treating hepatic encephalopathy
US12/572,344 2009-10-02
US26252509P 2009-11-18 2009-11-18
US61/262,525 2009-11-18
US61/305,854 2010-02-18
US30693510P 2010-02-22 2010-02-22
US61/306,935 2010-02-22
US30741710P 2010-02-23 2010-02-23
US61/307,417 2010-02-23
US31679610P 2010-03-23 2010-03-23
US61/316,796 2010-03-23
PCT/US2010/037131 WO2011005388A1 (fr) 2009-06-02 2010-06-02 Procédés de traitement de l'encéphalopathie hépatique

Publications (1)

Publication Number Publication Date
CA2763894A1 true CA2763894A1 (fr) 2011-01-13

Family

ID=45525156

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2763894A Abandoned CA2763894A1 (fr) 2009-06-02 2010-06-02 Utilisation de la rifaximine pour maintenir la remission de l'encephalopathie hepatique

Country Status (1)

Country Link
CA (1) CA2763894A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016085887A1 (fr) * 2014-11-24 2016-06-02 Ucl Business Plc Traitement de maladies associées à l'activation des cellules hépatiques étoilées aux moyen de thérapies d'abaissement du taux d'ammoniac
US10173964B2 (en) 2009-04-03 2019-01-08 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US10610506B2 (en) 2004-11-26 2020-04-07 Ucl Business Ltd Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11066352B2 (en) 2017-05-11 2021-07-20 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate
US11266620B2 (en) 2009-06-08 2022-03-08 Ucl Business Ltd Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610506B2 (en) 2004-11-26 2020-04-07 Ucl Business Ltd Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US10173964B2 (en) 2009-04-03 2019-01-08 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US10550069B2 (en) 2009-04-03 2020-02-04 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US11161802B2 (en) 2009-04-03 2021-11-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US11266620B2 (en) 2009-06-08 2022-03-08 Ucl Business Ltd Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
US10039735B2 (en) 2014-11-24 2018-08-07 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
WO2016085887A1 (fr) * 2014-11-24 2016-06-02 Ucl Business Plc Traitement de maladies associées à l'activation des cellules hépatiques étoilées aux moyen de thérapies d'abaissement du taux d'ammoniac
US10525029B2 (en) 2014-11-24 2020-01-07 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
CN107206021A (zh) * 2014-11-24 2017-09-26 Ucl商业有限公司 使用降氨疗法治疗与肝星状细胞激活相关的疾病
US11040021B2 (en) 2014-11-24 2021-06-22 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
IL281349B (en) * 2014-11-24 2022-09-01 Ucl Business Ltd Treatment of diseases related to hepatic stellate cell activity using ammonia-lowering treatments
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11066352B2 (en) 2017-05-11 2021-07-20 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate

Similar Documents

Publication Publication Date Title
US10314828B2 (en) Methods of treating hepatic encephalopathy
US9629828B2 (en) Methods of treating traveler's diarrhea and hepatic encephalopathy
US11633384B2 (en) Methods of treating hepatic encephalopathy
EP3964066A1 (fr) Procédés de traitement de l'encéphalopathie hépatique
CA2763894A1 (fr) Utilisation de la rifaximine pour maintenir la remission de l'encephalopathie hepatique
US20230091701A1 (en) Methods of treating hepatic encephalopathy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150525

FZDE Dead

Effective date: 20210125